Canagliflozin is an SGLT2 inhibitor that lowers blood glucose by blocking its reabsorption in the kidneys, causing it to be excreted in urine. This mechanism has downstream effects on cellular energy sensing pathways like AMPK, mimicking aspects of caloric restriction. Its primary relevance to healthspan is its robust, evidence-backed ability to protect cardiovascular and renal function, two key systems that decline with age.
Verdict
Potent cardio-renal protection, but requires medical supervision for significant side effects.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$50 - $600
Protocol
- 100mg taken once daily in the morning, often before the first meal.
Flags
- Increased risk of genital mycotic infections and urinary tract infections.
- Risk of euglycemic diabetic ketoacidosis (DKA), a serious medical emergency.
- May cause dehydration and hypotension, especially when combined with diuretics.
- Associated with an increased risk of bone fractures.
- Requires medical supervision and is a prescription-only medication.